| Business Summary | | Cima
Labs
Inc.
develops
and
manufactures
pharmaceutical
products
based
on
its
proprietary
OraSolv
and
DuraSolv
fast-dissolve
technologies.
The
Company
manufactures
five
pharmaceutical
brands
utilizing
its
DuraSolv
and
OraSolv
technologies.
They
consist
of
three
prescription
and
two
over-the-counter
brands.
These
products
include
Triaminic
Softchews
for
Novartis;
Tempra
FirsTabs
for
a
Canadian
affiliate
of
Bristol-Myers
Squibb;
Zomig-ZMT
and
its
equivalent
for
the
European
market,
Zomig
Rapimelt,
for
AstraZeneca;
Remeron
SolTab
for
Organon,
and
NuLev
for
Schwarz
Pharma.
In
addition
to
OraSolv
and
DuraSolv,
the
Company
is
developing
transmucosal
oral
drug
delivery
technologies.
These
technologies
include
OraVescent
SL
for
drug
delivery
under
the
tongue,
OraVescent
BL
for
drug
delivery
between
the
gum
and
the
cheek
and
OraVescent
SS
for
swallowable
site-specific
drug
delivery
in
the
gastrointestinal
tract. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cima
Labs
Inc.
is
a
drug
delivery
company
that
develops
and
manufactures
products
based
upon
its
patented
OraSolv
technology
for
marketing
by
multinational
pharmaceuticals
companies.
For
the
six
months
ended
6/30/01,
revenues
rose
22%
to
$14
million.
Net
income
before
accounting
change
totaled
$6.7
million,
up
from
$942
thousand.
Results
reflect
an
increase
in
shipments
of
branded
prescription
products,
improved
margins,
and
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Terrence Glarner, 57 Chairman | -- | -- | John Siebert, Ph.D., 61 Pres
and CEO | $454K | $2.4M | John Hontz, Ph.D., 44 COO | 291K | 2.2M | David Feste, 49 VP,
CFO, Sec. | 173K | 640K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|